Loading...
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease
BACKGROUND: Data from trials of vedolizumab for inflammatory bowel disease and from real-world studies suggest an exposure-response relationship, such that vedolizumab trough levels may predict clinical and endoscopic outcomes. OBJECTIVE: The purpose of this study was to evaluate in a prospective ob...
Na minha lista:
| Udgivet i: | United European Gastroenterol J |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
SAGE Publications
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6826518/ https://ncbi.nlm.nih.gov/pubmed/31700632 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2050640619873784 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|